- Home
- FL vs BEAM Comparison
FL vs BEAM Comparison
Compare FL & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FL
- BEAM
- Stock Information
- Founded
- FL 1879
- BEAM 2017
- Country
- FL United States
- BEAM United States
- Employees
- FL N/A
- BEAM N/A
- Industry
- FL Clothing/Shoe/Accessory Stores
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FL Consumer Discretionary
- BEAM Health Care
- Exchange
- FL Nasdaq
- BEAM Nasdaq
- Market Cap
- FL 2.3B
- BEAM 1.8B
- IPO Year
- FL N/A
- BEAM 2020
- Fundamental
- Price
- FL $23.73
- BEAM $16.19
- Analyst Decision
- FL Hold
- BEAM Strong Buy
- Analyst Count
- FL 15
- BEAM 11
- Target Price
- FL $21.00
- BEAM $48.90
- AVG Volume (30 Days)
- FL 9.8M
- BEAM 1.9M
- Earning Date
- FL 05-29-2025
- BEAM 05-06-2025
- Dividend Yield
- FL N/A
- BEAM N/A
- EPS Growth
- FL N/A
- BEAM N/A
- EPS
- FL N/A
- BEAM N/A
- Revenue
- FL $7,903,000,000.00
- BEAM $63,578,000.00
- Revenue This Year
- FL $2.70
- BEAM N/A
- Revenue Next Year
- FL $1.95
- BEAM $10.59
- P/E Ratio
- FL N/A
- BEAM N/A
- Revenue Growth
- FL N/A
- BEAM N/A
- 52 Week Low
- FL $11.00
- BEAM $13.53
- 52 Week High
- FL $33.94
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- FL 78.09
- BEAM 39.35
- Support Level
- FL $23.76
- BEAM $15.35
- Resistance Level
- FL $24.05
- BEAM $17.47
- Average True Range (ATR)
- FL 0.26
- BEAM 0.90
- MACD
- FL 0.28
- BEAM -0.07
- Stochastic Oscillator
- FL 96.15
- BEAM 24.71
About FL Foot Locker Inc.
Foot Locker Inc operates footwear and apparel retailer in North America, Europe, Australia, New Zealand, and Asia, and has licensed store presence in the Middle East, Europe, and Asia. The company mainly sells athletically inspired shoes and apparel. Foot Locker's merchandise comes from only a few suppliers, with Nike providing the majority. Its portfolio of brands includes Foot Locker, Kids Foot Locker, Champs Sports, WSS, and atmos. The company has omnichannel capabilities to bridge the digital world and physical stores, including order-in-store, buy online and pickup-in-store, and buy online and ship-from-store, as well as e-commerce. It has three operating segments, North America, EMEA, and Asia Pacific.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.